Geron Corp (GERN) 3.03 $GERN
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Some Color On Geron's Presentation At The BIO Conference
Kanak Kanti De - at Seeking Alpha - Tue Feb 10, 8:15PM CST
GERN: 3.03 (unch)
Momentum Indicators for Biotech Equities - PDL BioPharma, Geron, Celldex Therapeutics, XOMA Corp., and Juno Therapeutics
PR Newswire - Mon Feb 09, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Geron Corporation (NASDAQ: GERN), Celldex Therapeutics Inc. (NASDAQ: CLDX), XOMA Corporation (NASDAQ: XOMA), and Juno Therapeutics Inc. (NASDAQ: JUNO). Free research report on PDL BioPharma can be accessed at http://get.Investor-Edge.com/pdf/?c=PDL%20Bio...amp;s=PDLI. On Friday, February 06, 2015, the NASDAQ Composite ended at 4,744.40, down 0.43%, the Dow Jones Industrial Average declined 0.34%, to finish the day at 17,824.29, and the S&P 500 closed at 2,055.47, down 0.34%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 806.81, down 0.84%, while the index has advanced 4.07% in the last three months. Register for your complimentary reports at the links given below.
GERN: 3.03 (unch), CLDX: 20.97 (+0.53), JUNO: 40.52 (+0.18), XOMA: 3.41 (-0.01), PDLI: 7.28 (+0.03)
3 All-or-Nothing Biotech Stocks We're Closely Watching
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:10AM CST
There may be no other industry as prone to hit-or-miss investments as biotechnology. An astounding 90% of drugs that enter phase 1 clinical trials never reach commercialization, and that means failure is far more common than success. As a result,...
JNJ: 99.62 (+1.18), ESPR: 67.13 (-0.33), GERN: 3.03 (unch), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), PBYI: 205.26 (+2.75)
Geron to Present at the 17th Annual BIO CEO & Investor Conference
Thomson Reuters ONE - Mon Feb 02, 6:15AM CST
MENLO PARK, Calif., February 2, 2015 - Geron Corporation (Nasdaq: GERN) today announced that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company at the 17th Annual BIO CEO & Investor Conference in New York. The presentation is scheduled to occur on Monday, February 9, at 2:00 p.m. Eastern Time.
GERN: 3.03 (unch)
30 Reasons I Like Geron
Kanak Kanti De - at Seeking Alpha - Tue Jan 27, 3:17PM CST
GERN: 3.03 (unch)
3 Health Care Stocks Under $10 to Watch: MannKind and More
at The Street - Tue Jan 27, 12:05PM CST
Keep an eye on these under-$10 health care stocks making big moves to the upside.
HNSN: 1.05 (+0.02), GERN: 3.03 (unch), MNKD: 7.00 (+0.02)
Has Geron Undersold Itself To Janssen?
Kanak Kanti De - at Seeking Alpha - Tue Jan 20, 12:30PM CST
JNJ: 99.62 (+1.18), GERN: 3.03 (unch)
Seeking Alpha's Biotech Weekly: Roche Takes Control, Shire's A Buyer, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jan 16, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ZIOP: 9.64 (-0.35), ARWR: 6.77 (+0.21), XON: 39.30 (+1.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNKD: 7.00 (+0.02), RGDO: 1.17 (+0.02), HUM: 152.67 (-1.06), ETRM: 1.21 (+0.06), FMI: 48.88 (+0.17), GILD: 101.90 (+1.10), GERN: 3.03 (unch), SHPG: 239.82 (+6.11), SRPT: 12.76 (+0.11)
Trade-Ideas: Geron (GERN) Is Today's Strong On High Relative Volume Stock
at The Street - Wed Jan 14, 9:03AM CST
Trade-Ideas LLC identified Geron (GERN) as a strong on high relative volume candidate
GERN: 3.03 (unch)
Hot Stock: Geron, Shares Gain 8.1% (GERN)
Comtex SmarTrend(R) - Tue Jan 13, 11:38AM CST
Geron (NASDAQ:GERN) is one of today's best performing low-priced stocks, up 8.1% to $3.40 on 1.1x average daily volume. Geron has traded 4.2 million shares thus far today, vs. average volume of 3.7 million shares per day. The stock has outperformed the Dow (8.1% to the Dow's 0.9%) and outperformed the S&P 500 (8.1% to the S&P's 0.6%) during today's trading.
GERN: 3.03 (unch)
It's Time To Invest In Geron: Johnson & Johnson Thinks So
Stock Doctor - at Seeking Alpha - Tue Jan 13, 7:47AM CST
Those investors that follow my articles know that I like to write about biotechnology stocks that are currently undervalued with significant upcoming catalysts which have a high chance of success. This strategy has allowed me and my followers to...
JNJ: 99.62 (+1.18), GERN: 3.03 (unch)
The Small-Cap Stock I'm Watching in 2015
Motley Fool Staff - Motley Fool - Wed Jan 07, 9:00AM CST
Small-cap stocks can offer investors impressive gains, but they also come with their fair share of risk. That makes it particularly important to research small-cap companies before putting them in your portfolio. However, knowing which small caps to...
JNJ: 99.62 (+1.18), ENPH: 15.15 (+0.37), GERN: 3.03 (unch), BTX: 4.07 (+0.05), OPHT: 51.11 (+0.12)
3 Biotech Stocks That Could Double in 2015
Motley Fool Staff - Motley Fool - Mon Dec 29, 5:50AM CST
Few industries offer the promise and pitfalls of biotechnology. Clinical wins and losses can lead to extraordinary stock gains or falls that make the sector best suited for only the most risk-tolerant investor. However, for investors willing to take...
JNJ: 99.62 (+1.18), GERN: 3.03 (unch), SHPG: 239.82 (+6.11), INCY: 75.94 (+0.28), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00), EXEL: 2.48 (+0.20)
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.44 (-0.01), ASPX: 65.76 (+2.76), MDVN: 104.71 (+0.67), CYCC: 0.62 (-0.01), OPK: 13.80 (-0.28), NLNK: 38.84 (+1.51), JUNO: 40.52 (+0.18), REGN: 402.40 (+0.66), MYGN: 34.03 (+0.40), PFE: 34.64 (-0.23), IMGN: 7.19 (unch), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), BLRX: 1.87 (-0.02), OREX: 5.55 (+0.10), DVA: 73.10 (-3.29), BLCM: 20.00 (-0.81), CBST: 101.94 (+0.14), GILD: 101.90 (+1.10), GERN: 3.03 (unch), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Geron Enters 2015 On A More Assured Note
Kanak Kanti De - at Seeking Alpha - Thu Dec 18, 2:28PM CST
GERN: 3.03 (unch)
Biotech Stocks Technical Insight -- ARIAD Pharma, Geron, PDL BioPharma, Cytori Therapeutics, and Navidea Biopharma
PR Newswire - Thu Dec 18, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Geron Corporation (NASDAQ: GERN), PDL BioPharma Inc. (NASDAQ: PDLI), Cytori Therapeutics Inc. (NASDAQ: CYTX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, December 17, 2014, surged as the Dow Jones Industrial Average finished at 17,356.87, up 1.69% and the NASDAQ Composite closed at 4,644.31, up 2.12%. The S&P 500 finished the session 2.04% higher at 2,012.89. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Index ended the day at 791.66, up 1.90%, with the index advancing 6.28% in the previous three months. Register for your complimentary reports on these five stocks at:
NAVB: 1.60 (unch), CYTX: 0.47 (unch), GERN: 3.03 (unch), ARIA: 7.35 (+0.45), PDLI: 7.28 (+0.03)
Myelofibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/5dgl3c/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca PLC - Eli Lilly and Company - Gilead Sciences, Inc. - Novartis AG - Cell Therapeutics, Inc. - Celgene Corporation - Incyte Corporation - Geron Corporation - MEI Pharma, Inc. - Threshold Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - Promedior, Inc. For more information visit http://www.researchandmarkets.com/research/5d...lofibrosis
GILD: 101.90 (+1.10), GERN: 3.03 (unch), INCY: 75.94 (+0.28), AZN: 69.96 (+0.20), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), MEIP: 5.00 (-0.04), CELGZ: 3.17 (-0.04), XLRN: 38.02 (+0.07)
Geron reports 3Q loss
Automated Insights - Wed Dec 17, 2:29PM CST
MENLO PARK, Calif. (AP) _ Geron Corp. (GERN) on Wednesday reported a loss of $9.5 million, or 6 cents per share, in its third quarter.
GERN: 3.03 (unch)
Market Has Not Yet Noticed Potential in Geron (GERN); Have You? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 8:02AM CST
Geron is seeing solid earnings estimate revisions and has an impressive Zacks Rank but that is not yet reflected in its price
GERN: 3.03 (unch)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Some Color On Geron's Presentation At The BIO Conference
Kanak Kanti De - at Seeking Alpha - Tue Feb 10, 8:15PM CST
GERN: 3.03 (unch)
Momentum Indicators for Biotech Equities - PDL BioPharma, Geron, Celldex Therapeutics, XOMA Corp., and Juno Therapeutics
PR Newswire - Mon Feb 09, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Geron Corporation (NASDAQ: GERN), Celldex Therapeutics Inc. (NASDAQ: CLDX), XOMA Corporation (NASDAQ: XOMA), and Juno Therapeutics Inc. (NASDAQ: JUNO). Free research report on PDL BioPharma can be accessed at http://get.Investor-Edge.com/pdf/?c=PDL%20Bio...amp;s=PDLI. On Friday, February 06, 2015, the NASDAQ Composite ended at 4,744.40, down 0.43%, the Dow Jones Industrial Average declined 0.34%, to finish the day at 17,824.29, and the S&P 500 closed at 2,055.47, down 0.34%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 806.81, down 0.84%, while the index has advanced 4.07% in the last three months. Register for your complimentary reports at the links given below.
GERN: 3.03 (unch), CLDX: 20.97 (+0.53), JUNO: 40.52 (+0.18), XOMA: 3.41 (-0.01), PDLI: 7.28 (+0.03)
3 All-or-Nothing Biotech Stocks We're Closely Watching
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:10AM CST
There may be no other industry as prone to hit-or-miss investments as biotechnology. An astounding 90% of drugs that enter phase 1 clinical trials never reach commercialization, and that means failure is far more common than success. As a result,...
JNJ: 99.62 (+1.18), ESPR: 67.13 (-0.33), GERN: 3.03 (unch), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), PBYI: 205.26 (+2.75)
Geron to Present at the 17th Annual BIO CEO & Investor Conference
Thomson Reuters ONE - Mon Feb 02, 6:15AM CST
MENLO PARK, Calif., February 2, 2015 - Geron Corporation (Nasdaq: GERN) today announced that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company at the 17th Annual BIO CEO & Investor Conference in New York. The presentation is scheduled to occur on Monday, February 9, at 2:00 p.m. Eastern Time.
GERN: 3.03 (unch)
30 Reasons I Like Geron
Kanak Kanti De - at Seeking Alpha - Tue Jan 27, 3:17PM CST
GERN: 3.03 (unch)
3 Health Care Stocks Under $10 to Watch: MannKind and More
at The Street - Tue Jan 27, 12:05PM CST
Keep an eye on these under-$10 health care stocks making big moves to the upside.
HNSN: 1.05 (+0.02), GERN: 3.03 (unch), MNKD: 7.00 (+0.02)
Has Geron Undersold Itself To Janssen?
Kanak Kanti De - at Seeking Alpha - Tue Jan 20, 12:30PM CST
JNJ: 99.62 (+1.18), GERN: 3.03 (unch)
Seeking Alpha's Biotech Weekly: Roche Takes Control, Shire's A Buyer, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jan 16, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ZIOP: 9.64 (-0.35), ARWR: 6.77 (+0.21), XON: 39.30 (+1.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNKD: 7.00 (+0.02), RGDO: 1.17 (+0.02), HUM: 152.67 (-1.06), ETRM: 1.21 (+0.06), FMI: 48.88 (+0.17), GILD: 101.90 (+1.10), GERN: 3.03 (unch), SHPG: 239.82 (+6.11), SRPT: 12.76 (+0.11)
Trade-Ideas: Geron (GERN) Is Today's Strong On High Relative Volume Stock
at The Street - Wed Jan 14, 9:03AM CST
Trade-Ideas LLC identified Geron (GERN) as a strong on high relative volume candidate
GERN: 3.03 (unch)
Hot Stock: Geron, Shares Gain 8.1% (GERN)
Comtex SmarTrend(R) - Tue Jan 13, 11:38AM CST
Geron (NASDAQ:GERN) is one of today's best performing low-priced stocks, up 8.1% to $3.40 on 1.1x average daily volume. Geron has traded 4.2 million shares thus far today, vs. average volume of 3.7 million shares per day. The stock has outperformed the Dow (8.1% to the Dow's 0.9%) and outperformed the S&P 500 (8.1% to the S&P's 0.6%) during today's trading.
GERN: 3.03 (unch)
It's Time To Invest In Geron: Johnson & Johnson Thinks So
Stock Doctor - at Seeking Alpha - Tue Jan 13, 7:47AM CST
Those investors that follow my articles know that I like to write about biotechnology stocks that are currently undervalued with significant upcoming catalysts which have a high chance of success. This strategy has allowed me and my followers to...
JNJ: 99.62 (+1.18), GERN: 3.03 (unch)
The Small-Cap Stock I'm Watching in 2015
Motley Fool Staff - Motley Fool - Wed Jan 07, 9:00AM CST
Small-cap stocks can offer investors impressive gains, but they also come with their fair share of risk. That makes it particularly important to research small-cap companies before putting them in your portfolio. However, knowing which small caps to...
JNJ: 99.62 (+1.18), ENPH: 15.15 (+0.37), GERN: 3.03 (unch), BTX: 4.07 (+0.05), OPHT: 51.11 (+0.12)
3 Biotech Stocks That Could Double in 2015
Motley Fool Staff - Motley Fool - Mon Dec 29, 5:50AM CST
Few industries offer the promise and pitfalls of biotechnology. Clinical wins and losses can lead to extraordinary stock gains or falls that make the sector best suited for only the most risk-tolerant investor. However, for investors willing to take...
JNJ: 99.62 (+1.18), GERN: 3.03 (unch), SHPG: 239.82 (+6.11), INCY: 75.94 (+0.28), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00), EXEL: 2.48 (+0.20)
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.44 (-0.01), ASPX: 65.76 (+2.76), MDVN: 104.71 (+0.67), CYCC: 0.62 (-0.01), OPK: 13.80 (-0.28), NLNK: 38.84 (+1.51), JUNO: 40.52 (+0.18), REGN: 402.40 (+0.66), MYGN: 34.03 (+0.40), PFE: 34.64 (-0.23), IMGN: 7.19 (unch), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), BLRX: 1.87 (-0.02), OREX: 5.55 (+0.10), DVA: 73.10 (-3.29), BLCM: 20.00 (-0.81), CBST: 101.94 (+0.14), GILD: 101.90 (+1.10), GERN: 3.03 (unch), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Geron Enters 2015 On A More Assured Note
Kanak Kanti De - at Seeking Alpha - Thu Dec 18, 2:28PM CST
GERN: 3.03 (unch)
Biotech Stocks Technical Insight -- ARIAD Pharma, Geron, PDL BioPharma, Cytori Therapeutics, and Navidea Biopharma
PR Newswire - Thu Dec 18, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Geron Corporation (NASDAQ: GERN), PDL BioPharma Inc. (NASDAQ: PDLI), Cytori Therapeutics Inc. (NASDAQ: CYTX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, December 17, 2014, surged as the Dow Jones Industrial Average finished at 17,356.87, up 1.69% and the NASDAQ Composite closed at 4,644.31, up 2.12%. The S&P 500 finished the session 2.04% higher at 2,012.89. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Index ended the day at 791.66, up 1.90%, with the index advancing 6.28% in the previous three months. Register for your complimentary reports on these five stocks at:
NAVB: 1.60 (unch), CYTX: 0.47 (unch), GERN: 3.03 (unch), ARIA: 7.35 (+0.45), PDLI: 7.28 (+0.03)
Myelofibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/5dgl3c/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca PLC - Eli Lilly and Company - Gilead Sciences, Inc. - Novartis AG - Cell Therapeutics, Inc. - Celgene Corporation - Incyte Corporation - Geron Corporation - MEI Pharma, Inc. - Threshold Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - Promedior, Inc. For more information visit http://www.researchandmarkets.com/research/5d...lofibrosis
GILD: 101.90 (+1.10), GERN: 3.03 (unch), INCY: 75.94 (+0.28), AZN: 69.96 (+0.20), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), MEIP: 5.00 (-0.04), CELGZ: 3.17 (-0.04), XLRN: 38.02 (+0.07)
Geron reports 3Q loss
Automated Insights - Wed Dec 17, 2:29PM CST
MENLO PARK, Calif. (AP) _ Geron Corp. (GERN) on Wednesday reported a loss of $9.5 million, or 6 cents per share, in its third quarter.
GERN: 3.03 (unch)
Market Has Not Yet Noticed Potential in Geron (GERN); Have You? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 8:02AM CST
Geron is seeing solid earnings estimate revisions and has an impressive Zacks Rank but that is not yet reflected in its price
GERN: 3.03 (unch)
